Boundless Bio

Edit info

Founded: 2019

Location: La Jolla, CA

Employee range: 50 - 200

Clinical stage: Clin1

Therapy area: Oncology

Drug types: ONC

Lead product: BBI-355

Funding: $100M C May 2023; $105M B Apr 2021; $46M Sep 2019

Investors: ARCH Venture Partners, City Hill, Leaps by Bayer, RA Capital, Nextech Invest, Fidelity Management & Research Company LLC, Redmile Group, Wellington Management, Surveyor Capital (a Citadel company), PFM Health Sciences, Logos Capital, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital of Tavistock Group, Alexandria Venture Investments

boundlessbio.com

linkedin.com

job board

Business:

Cancer Treatments targeting extra-chromosomal DNA

Drug notes:

BBI-825 Clin0 oncology; EcHo Clin0 oncology diagnostic; 2 programs RD oncology

About:

Boundless Bio is developing therapeutics directed against extrachromosomal DNA (eDNA) to treat the most intractable cancers. ecDNAs are large units of circular DNA that reside within the cell nucleus yet are distinct from the chromosomal DNA. As ecDNAs can encode genes, they provide a mechanism for higher copy numbers of oncogenes, genes that are known to drive aggressive tumor growth and resistance to cancer treatments. Boundless has identified ecDNA as a differentiating feature of cancer cells that does not exist in normal cells. By further characterizing the biology of ecDNAs using their Spyglass platform, Boundless is generating a broad pipeline of ecDNA-directed therapies (ecDTx) to target gene amplified cancers.

Main

Contact: recruit@workinbiotech.com